SCHEMBL24257774

SCHEMBL24257774

Cc1c(-c2ccc3ncccc3c2)cnc(C(=O)O)c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.53
NPC1 O15118 2/20 0.48
POLB P06746 2/20 0.48
RAB9A P51151 1/20 0.48
AKR1C3 P42330 1/20 0.47
AKR1C2 P52895 1/20 0.47
CCNC P24863 1/20 0.46
CDK8 P49336 1/20 0.46
AR P10275 1/20 0.46
ALDH1A1 P00352 1/20 0.42
PFKFB3 Q16875 1/20 0.42
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
PLK1 P53350 1/20 0.41
ADORA2A P29274 4/20 0.41
DYRK1A Q13627 1/20 0.41
GSK3B P49841 1/20 0.40
CLK1 P49759 2/20 0.40
MMP9 P14780 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30453199 1.00 MCL1 (0.53) MCL1NPC1POLBRAB9AAKR1C3
SCHEMBL24257637 0.85 EGLN1 (0.50) MCL1CCNCCDK8
SCHEMBL30452349 0.84 AKR1C3 (0.42) MCL1NPC1POLBRAB9AAKR1C3
SCHEMBL24257500 0.84 AKR1C3 (0.42) MCL1NPC1POLBRAB9AAKR1C3
SCHEMBL24257788 0.79 KDM4E (0.46) MCL1CCNCCDK8ALDH1A1ALOX15
SCHEMBL30452524 0.79 KDM4E (0.46) MCL1CCNCCDK8ALDH1A1ALOX15
SCHEMBL24257702 0.79 AR (0.45) CCNCCDK8ARDYRK1AGSK3B
SCHEMBL30453303 0.79 AR (0.45) CCNCCDK8ARDYRK1AGSK3B
SCHEMBL30546825 0.79 MCL1 (0.56) MCL1NPC1POLBRAB9AAKR1C3
SCHEMBL18425045 0.77 MCL1 (0.49) MCL1NPC1POLBRAB9AAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 MCL1 2389/4885NPC1 4011/4885POLB 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.